Abpro Holdings (ABP) Form 8-K Summary

Date Reported: November 4, 2025

Abpro Holdings announced a key strategic development via Item 7.01 Regulation FD Disclosure:

• Partnership Event: Abpro and Celltrion, Inc. will present new preclinical data.
• Asset Focus: Data pertains to CT-P72/ABP-102, a tetravalent bispecific antibody targeting HER2 and CD3.
• Venue: Presentation scheduled for the SITC 2025 Annual Meeting (Nov 6-10).

Critical Investor Takeaway: The filing highlights progress and collaboration on a significant pipeline asset (ABP-102) ahead